Association between Drug and Vaccine Use and Acute Immune Thrombocytopenia in Childhood
- Federica BertuolaAffiliated withDepartment of Pediatrics, University of Padua
- , Carla MorandoAffiliated withDepartment of Pediatrics, University of Padua
- , Francesca Menniti-IppolitoAffiliated withNational Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health
- , Roberto Da CasAffiliated withNational Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health
- , Annalisa CapuanoAffiliated withDepartment of Experimental Medicine, Section of Pharmacology “L. Donatelli”, Second University of Naples
- , Giorgio PerilongoAffiliated withDepartment of Pediatrics, University of Padua
- , Liviana Da DaltAffiliated withDepartment of Pediatrics, University of Padua Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Immune thrombocytopenic purpura (ITP) is an immuno-mediated disease characterized by a decrease in platelet count and, in its more severe forms, by bleeding symptoms. Many drugs have been implicated in the pathogenesis of drug-induced thrombocytopenia in adults; only limited data on drug-related ITP in children have been published.
Objective: Our study was set up to evaluate the consistency of the association between drug and vaccine use and ITP in children.
Study Design: This study is part of an Italian multicentre study on adverse drug reactions in children, coordinated by the Italian National Institute of Health, which was started in November 1999 and is ongoing.
Patients or Other Participants: The study was conducted by enrolling all children aged more than 1 month who were hospitalized through the paediatric emergency department for the following conditions: thrombocytopenia (platelet count <100×103/L); acute neurological disorders; non-infectious mucocutaneous diseases and vasculitis; and endoscopically confirmed gastroduodenal lesions and/or clinically defined haematemesis and melaena. Children with chronic pathologies or concomitant diagnoses of cancer or immunodeficiency were not included in our study.
Main Outcome Measure: During hospital admission, a physician interviewed parents using a structured questionnaire. The main aim of the interview was to collect information on drug exposure in a time period of 3 weeks and vaccine exposure in a period of 6 weeks preceding hospitalization. Using a case-control study design, exposure of children with thrombocytopenia (cases) to drugs and vaccines was compared with similar exposure of children with gastroduodenal lesions and neurological disorders (controls); this allowed us to estimate the odds ratios (ORs) of the occurrence of thrombo-cytopenia associated with the use of drugs or vaccines.
Results: Up to December 2007, the study population included 387 cases of thrombocytopenia and 1924 controls. Despite the low platelet count, ITP was generally a mild disease, without serious bleeding in the majority of cases and associated with a short length of hospital stay. After adjusting for concurrent use of other drugs, use of the antibacterials was associated with a more than 2-fold increase in the risk of developing ITP (OR 2.4; 95% CI 1.8, 3.1). Mucolytics and NSAIDs were associated with an OR of 1.9; 95% CI 1.2, 2.9 and 1.5; 95% CI 1.0, 2.1 respectively, while paracetamol (acetaminophen) was associated with an OR of 1.5; 95% CI 1.2, 2.0. MMR vaccination was associated with an increased risk of developing ITP (OR 2.4; 95% CI 1.2, 4.7).
Conclusions: The results of this study provide evidence for an association between ITP and exposure to selected antibacterials, NSAIDs, paracetamol, mucolytics and MMR vaccination.
- Association between Drug and Vaccine Use and Acute Immune Thrombocytopenia in Childhood
Volume 33, Issue 1 , pp 65-72
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Pediatrics, University of Padua, Via Giustiniani 3, 35128, Padova, Italy
- 2. National Centre for Epidemiology, Surveillance and Health Promotion, National Institute of Health, Rome, Italy
- 3. Department of Experimental Medicine, Section of Pharmacology “L. Donatelli”, Second University of Naples, Naples, Italy